Oct 25, 2020

AI-powered blood analysis to "improve outcome of diagnosis"

AI
blood analysis
digital imaging
Leila Hawkins
2 min
AI-powered blood analysis to "improve outcome of diagnosis"
Using artificial intelligence to assess blood samples could improve care outcomes and reduce time...

A new microscope that uses artificial intelligence to analyse blood samples is set to be commercially available in early 2021. 

Israeli startup Scopio Labs have announced that the AI-powered X100 microscope has been approved by the US Food and Drug Administration (FDA). 

Scopio's microscope aims to reduce human error, as most pathologists use manual tools to make in-depth diagnosis when analysing blood samples. 

The X100 uses innovative computer vision tools to capture digital scans, along with advanced imaging techniques. The microscope's Full Field Peripheral Blood Smear (Full Field PBS) application includes a tailored decision support system to pre-classificy white blood cells into 16 classes, red blood cell morphology evaluations, platelet location and count. 

It also enables the pathologist to zoom in and out to view thousands of cells on a digital slide, at a resolution level of 100X. Scopio say such a high resolution has not been possible in a far so far. 

"Understanding the challenges lab technicians, hematologists and hematopathologists face when evaluating blood samples containing large numbers of morphologically-unique cells in a timely fashion, we designed our solution specifically for hematology labs where we can improve quality of care, consistency of results and reduce review time” said Scopio Labs’ CEO and Co-Founder, Itai Hayut. 

“We are thrilled to receive FDA clearance following the successful completion of a multi-center study, as we bring our innovative solution to laboratories around the US to help improve the outcome of diagnosis and care.”  

Scopio Labs was founded in 2015 with the purpose of using advanced imaging and AI to find novel solutions to hematology diagnostics, by discovering actionable insights from vast amounts of data in the average blood sample and bone marrow aspirate. 

“The field of microscopy is poised for transformation, and I am enthusiastic about the prospects of Scopio Labs’ innovative application” said Michael D. Feldman, MD, PhD, Vice Chairman Clinical Services, Pathology and Laboratory Medicine at University of Pennsylvania School of Medicine. “With new digital technologies combining imaging and artificial intelligence being introduced into the laboratory, we can provide clinicians with tools that strengthen their capabilities.” 

The company has also created an AI-based decision support system for the veterinary sector which is currently used in veterinary clinics throughout the United States, United Kingdom and Ireland. 

The X100 microscope and Full Field PBS is available in Europe with CE mark certification granted earlier this year. Full commercial availability expected early in 2021.

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article